The ability of eight frailty instruments to identify adverse outcomes across different settings: the FRAILTOOLS project

Myriam Oviedo-Briones, Ángel Rodríguez-Laso, José Antonio Carnicero, Barbara Gryglewska, Alan J Sinclair, Francesco Landi, Bruno Vellas, Fernando Rodríguez Artalejo, Marta Checa-López, Leocadio Rodriguez-Mañas, Myriam Oviedo-Briones, Ángel Rodríguez-Laso, José Antonio Carnicero, Barbara Gryglewska, Alan J Sinclair, Francesco Landi, Bruno Vellas, Fernando Rodríguez Artalejo, Marta Checa-López, Leocadio Rodriguez-Mañas

Abstract

Background: To compare the performance of eight frailty instruments to identify relevant adverse outcomes for older people across different settings over a 12 month follow-up.

Methods: Observational longitudinal prospective study of people aged 75 + years enrolled in different settings (acute geriatric wards, geriatric clinic, primary care clinics, and nursing homes) across five European cities. Frailty was assessed using the following: Frailty Phenotype, SHARE-FI, 5-item Frailty Trait Scale (FTS-5), 3-item FTS (FTS-3), FRAIL scale, 35-item Frailty Index (FI-35), Gérontopôle Frailty Screening Tool, and Clinical Frailty Scale. Adverse outcomes ascertained at follow-up were as follows: falls, hospitalization, increase in limitation in basic (BADL) and instrumental activities of daily living (IADL), and mortality. Sensitivity, specificity, and capacity to predict adverse outcomes in logistic regressions by each instrument above age, gender, and multimorbidity were calculated.

Results: A total of 996 individuals were followed (mean age 82.2 SD 5.5 years, 61.3% female). In geriatric wards, the FI-35 (69.1%) and the FTS-5 (67.9%) showed good sensitivity to predict death and good specificity to predict BADL worsening (70.3% and 69.8%, respectively). The FI-35 also showed good sensitivity to predict BADL worsening (74.6%). In nursing homes, the FI-35 and the FTSs predicted mortality and BADL worsening with a sensitivity > 73.9%. In geriatric clinic, the FI-35, the FTS-5, and the FRAIL scale obtained specificities > 85% to predict BADL worsening. No instrument achieved high enough sensitivity nor specificity in primary care. All the instruments predict the risk for all the outcomes in the whole sample after adjusting for age, gender, and multimorbidity. The associations of these instruments that remained significant by setting were for BADL worsening in geriatric wards [FI-35 OR = 5.94 (2.69-13.14), FTS-3 = 3.87 (1.76-8.48)], nursing homes [FI-35 = 4.88 (1.54-15.44), FTS-5 = 3.20 (1.61-6.38), FTS-3 = 2.31 (1.27-4.21), FRAIL scale = 1.91 (1.05-3.48)], and geriatric clinic [FRAIL scale = 4.48 (1.73-11.58), FI-35 = 3.30 (1.55-7.00)]; for IADL worsening in primary care [FTS-5 = 3.99 (1.14-13.89)] and geriatric clinic [FI-35 = 3.42 (1.56-7.49), FRAIL scale = 3.27 (1.21-8.86)]; for hospitalizations in primary care [FI-35 = 3.04 (1.25-7.39)]; and for falls in geriatric clinic [FI-35 = 2.21 (1.01-4.84)].

Conclusions: No single assessment instrument performs the best for all settings and outcomes. While in inpatients several commonly used frailty instruments showed good sensitivities (mainly for mortality and BADL worsening) but usually poor specificities, the contrary happened in geriatric clinic. None of the instruments showed a good performance in primary care. The FI-35 and the FTS-5 showed the best profile among the instruments assessed.

Trial registration: ClinicalTrials.gov NCT02637518.

Keywords: Frailty; Geriatric clinic; Geriatric wards; Nursing homes; Primary care; Screening.

Conflict of interest statement

All authors declare no conflicts of interest. All participants gave informed, written consent prior to their inclusion in the study. The study was approved by the Ethics committee of each participating centre. It has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

References

    1. Reeves D, Pye S, Ashcroft DM, Clegg A, Kontopantelis E, Blakeman T, et al. The challenge of ageing populations and patient frailty: can primary care adapt? BMJ 2018;362:k3349.
    1. Ambagtsheer RC, Shafiabady N, Dent E, Seiboth C, Beilby J. The application of artificial intelligence (AI) techniques to identify frailty within a residential aged care administrative data set. Int J Med Inform 2020;136:104094.
    1. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging 2014;9:433–441.
    1. Abizanda P, Romero L, Sanchez‐Jurado PM, Atienzar‐Nunez P, Esquinas‐Requena JL, Garcia‐Nogueras I. Association between functional assessment instruments and frailty in older adults: the FRADEA study. J Frailty Aging 2012;1:162–168.
    1. Romero Rizos L, Abizanda Soler P. Fragilidad como predictor de episodios adversos en estudios epidemiológicos: Revisión de la literatura. Rev Esp Geriatr Gerontol 2013;48:285–289.
    1. Tavassoli N, Guyonnet S, Van Kan GA, Sourdet S, Krams T, Soto M, et al. Description of 1, 108 older patients referred by their physician to the “Geriatric Frailty clinic (G.F.C) for assessment of frailty and prevention of disability” at the gerontopole. J Nutr Heal Aging 2014;18:457–464.
    1. Daniels R, Van Rossum E, Beurskens A, Van Den Heuvel W, De Witte L. The predictive validity of three self‐report screening instruments for identifying frail older people in the community. BMC Public Health 2012;12:69.
    1. Warnier RMJ, van Rossum E, van Kuijk SMJ, Mulder WJ, Schols JMGA, Kempen GIJM. The Maastricht frailty screening tool for hospitalised patients (MFST‐HP) to identify non‐frail patients. Int J Clin Pract 2017;71:e13003.
    1. Pérez‐Zepeda MU, Cesari M, García‐Peña C. Predictive value of frailty indices for adverse outcomes in older adults. Rev Invest Clin 2016;68:92–98.
    1. Hogan DB, Freiheit EA, Strain LA, Patten S, Schmaltz H, Rolfson D, et al. Comparing frailty measures in their ability to predict adverse outcome among older residents of assisted living. BMC Geriatr 2012;12:10.1186/1471-2318-12-56
    1. Coelho T, Santos R, Paúl C, Gobbens RJJ, Fernandes L. Portuguese version of the Tilburg frailty indicator: transcultural adaptation and psychometric validation. Geriatr Gerontol Int 2015;15:951–960.
    1. Op het Veld L, Beurskens A, de Vet H, van Kuijk S, Hajema K, Kempen G, et al. The ability of four frailty screening instruments to predict mortality, hospitalization and dependency in (instrumental) activities of daily living. Eur J Ageing 2019;16:387–394.
    1. Oviedo‐Briones M, Laso ÁR, Carnicero JA, Cesari M, Grodzicki T, Gryglewska B, et al. A comparison of frailty assessment instruments in different clinical and social care settings: the Frailtools project. J Am Med Dir Assoc 2021;22:607.e7–607.e12.
    1. Checa‐López M, Oviedo‐Briones M, Pardo‐Gómez A, Gonzales Turin J, Guevara‐Guevara T, Carnicero J, et al. FRAILTOOLS study protocol: a comprehensive validation of frailty assessment tools to screen and diagnose frailty in different clinical and social settings and to provide instruments for integrated care in older adults. BMC Geriatr 2019;19:86.
    1. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstem AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–1379.
    1. Fried LP, Tangen CM, Walston J, Newman A, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Ser A Biol Sci Med Sci 2001;56:M146–M156.
    1. Cesari M, Gambassi G, Van Kan GA, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. Age Ageing 2014;43:10–12.
    1. Hoogendijk EO, van Kan GA, Guyonnet S, Vellas B, Cesari M. Components of the frailty phenotype in relation to the frailty index: results from the Toulouse frailty platform. J Am Med Dir Assoc 2015;16:855–859.
    1. Romero‐Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). BMC Geriatr 2010;10:57.
    1. García‐García FJ, Carcaillon L, Fernandez‐Tresguerres J, Alfaro A, Larrion J, Castillo C, et al. A new operational definition of frailty: the frailty trait scale. J Am Med Dir Assoc 2014;15:371.e7–371.e13.
    1. García‐García FJ, Carnicero JA, Losa‐Reyna J, Alfaro‐Acha A, Castillo‐Gallego C, Rosado Artalejo C, et al. Frailty trait scale–short form: a frailty instrument for clinical practice. J Am Med Dir Assoc 2020;Jan 28:pii: S1525‐8610(19)30868‐0;21:1260–1266.e2.
    1. Abellan Van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A. task force on frailty assessment of older people in clinical practice. J Nutr Heal Aging. 2008;12:29–37.
    1. Valdatta L, Perletti G, Maggiulli F, Tamborini F, Pellegatta I, Cherubino M. FRAIL scale as a predictor of complications and mortality in older patients undergoing reconstructive surgery for non‐melanoma skin cancer. Oncol Lett 2019;17:263–269.
    1. Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. Eur J Intern Med 2016;31:3–10.
    1. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24.
    1. Theou O, Rockwood MRH, Mitnitski A, Rockwood K. Disability and co‐morbidity in relation to frailty: how much do they overlap? Arch Gerontol Geriatr 2012;55:e1–e8.
    1. Vellas B, Balardy L, Gillette‐Guyonnet S, Abellan Van Kan G, Ghisolfi‐Marque A, Subra J, et al. Looking for frailty in community‐dwelling older persons: the Gerontopole Frailty Screening Tool (GFST). J Nutr Heal Aging. 2013;17:629–631.
    1. Rockwood K, Song X, MacKnight C, Bergman H, Hogan D, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;30(173:489–495.
    1. Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist 1969;3:179–186.
    1. Mahoney FI, Barthel DW. Funtional evaluation: the Barthel index. Md State Med J 1965;14:61–65.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
    1. Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol 1993;46:153–162.
    1. Bongue B, Buisson A, Dupre C, Beland F, Gonthier R, Crawford‐Achour É. Predictive performance of four frailty screening tools in community‐dwelling elderly. BMC Geriatr 2017;17:262.
    1. Ensrud KE, Ewing SK, Taylor BC, Fink H, Stone K, Cauley J, et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 2008;168:382–389.
    1. Rodríguez‐Laso Á, Caballero‐Mora MA, García Sanchez I, Rodríguez Manas L, Bernabei R, Gabrovec B, Rodríguez Mañas L, García‐Sánchez I, Hendry A, Roller‐Wirnsberger R, Liew A, Carriazo AM, Redon J, Galluzzo L, Viña J, Antoniadou E, Targowski T, di Furia L, Lattanzio F, Bozdog E & Telo M State of the art report on the prevention and management of frailty. . Published 2018. Accessed March 22, 2020. 892 897
    1. Woo J, Leung J, Morley JE. Comparison of frailty indicators based on clinical phenotype and the multiple deficit approach in predicting mortality and physical limitation. J Am Geriatr Soc 2012;60:1478–1486.
    1. Pritchard J, Kennedy C, Karampatos S, Loannidis G, Misiaszek B, Marr S, et al. Measuring frailty in clinical practice: a comparison of physical frailty assessment methods in a geriatric out‐patient clinic. BMC Geriatr 2017;17:264.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle 2021;12:2259–2261.

Source: PubMed

3
Předplatit